How Radioiodine Therapy Works
Radioiodine therapy uses the thyroid gland's natural ability to concentrate iodine, delivering targeted beta radiation that destroys hyperfunctioning thyroid tissue through short-range cellular damage. 1, 2
Mechanism of Action
Radioactive iodine-131 (¹³¹I) exploits the sodium/iodide symporter (NIS) present in thyroid follicular cells. After oral administration, the radioiodine is:
- Absorbed and concentrated by thyroid cells through the same mechanism as dietary iodine
- Retained within thyroid follicles where it emits short-range beta radiation (the therapeutic component) and gamma radiation (used for imaging)
- Causes cellular destruction through direct DNA damage and free radical formation from the beta particles, which have a tissue penetration of only 0.5-2mm 1, 3
The cytolytic effect of radiation leads to gradual thyroid cell death over weeks to months, reducing thyroid hormone production and ultimately achieving the therapeutic goal 4.
Therapeutic Objectives
The mechanism serves different purposes depending on the clinical context:
For Graves' Disease and Toxic Nodular Goiter:
- Destroys hyperfunctioning thyroid tissue to eliminate hyperthyroidism
- The ablative strategy intentionally aims for hypothyroidism rather than euthyroidism, as this provides more reliable disease control 4
For Differentiated Thyroid Cancer:
- Ablates residual normal thyroid tissue post-thyroidectomy
- Destroys microscopic cancer deposits that retain iodine-concentrating ability
- Treats known iodine-avid metastases 5, 6
Factors Affecting Efficacy
The absorbed radiation dose depends on:
- Thyroid uptake capacity: The percentage of administered radioiodine trapped by the gland
- Effective half-life: How long the radioiodine remains in the thyroid tissue (typically 3-7 days)
- Thyroid volume: Larger glands require higher activities to achieve adequate dose per gram of tissue 1, 3
Critical caveat: Antithyroid drugs significantly reduce radioiodine uptake and effective half-life, which is why they must be discontinued 3-7 days before treatment 4, 1. Conversely, TSH stimulation (endogenous or via recombinant human TSH) increases iodine uptake, enhancing therapeutic efficacy 3.
Dosing Strategies
Two main approaches exist 4:
- Fixed ablative dose: Typically 10-15 mCi (370-555 MBq) for Graves' disease, with success rates exceeding 80%
- Calculated dose: Based on thyroid volume and uptake measurements (150-200 μCi/g of tissue)
The ablative strategy is preferred because attempts to achieve euthyroidism with lower calculated doses rarely succeed long-term, as hypothyroidism develops progressively over years anyway 4.
Timeline of Effects
- Weeks 1-4: Possible transient worsening of hyperthyroidism due to radiation-induced thyroid cell lysis releasing stored hormones (occurs in 10-15% of patients) 4
- Months 1-3: Most patients achieve hypothyroidism with ablative doses 4
- Months 3-6: Delayed responders continue to show improvement 7
- Years 1+: Progressive increase in hypothyroidism incidence, reaching near 100% in Graves' disease 4, 3
The mechanism's effectiveness relies entirely on the thyroid tissue's ability to concentrate iodine—tissues that lose this capability (dedifferentiated thyroid cancers, some autonomous nodules) will not respond to radioiodine therapy 8.